​

Rapport Therapeutics (RAPP) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

RAPP Stock Forecast

Rapport Therapeutics (RAPP) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $43.50, with a high of $47.00 and a low of $40.00. This represents a 51.73% increase from the last price of $28.67.

$15 $22 $29 $36 $43 $50 High: $47 Avg: $43.5 Low: $40 Last Closed Price: $28.67

RAPP Stock Rating

Rapport Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

RAPP Price Target Upside V Benchmarks

TypeNameUpside
StockRapport Therapeutics51.73%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts135
Avg Price Target$47.00$47.00$45.00
Last Closing Price$28.67$28.67$28.67
Upside/Downside63.93%63.93%56.96%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2619---10
Feb, 2619---10
Jan, 2618---9
Dec, 2518---9
Nov, 2526---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 09, 2026Kambiz YazdiBTIG$47.00$29.9756.82%63.93%
Feb 02, 2026Benjamin BurnettWells Fargo$43.00$26.6161.59%49.98%
Dec 19, 2025Wells Fargo$51.00$29.6472.06%77.89%
Dec 09, 2025Douglas TsaoH.C. Wainwright$40.00$30.1632.63%39.52%
Sep 16, 2025Joon LeeTruist Financial$44.00$24.8577.06%53.47%
Jul 02, 2024Andrew TsaiJefferies$35.00$25.4437.58%22.08%
Jul 02, 2024Paul MatteisStifel Nicolaus$35.00$25.4437.58%22.08%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2026CitigroupMarket OutperformMarket Outperformhold
Mar 09, 2026BTIGBuyBuyhold
Mar 09, 2026Cowen & Co.BuyBuyhold
Feb 02, 2026Wells FargoOverweightinitialise
Jan 08, 2026CitigroupMarket OutperformMarket Outperformhold
Dec 19, 2025Goldman SachsBuyBuyhold
Dec 09, 2025H.C. WainwrightBuyBuyhold
Sep 08, 2025H.C. WainwrightBuyBuyhold
Jul 02, 2024Cowen & Co.Buyinitialise
Jul 02, 2024JefferiesBuyinitialise

Financial Forecast

EPS Forecast

Dec 24 Dec 25
Dec 24Dec 25
Reported$-0.38$-2.86
Avg Forecast$-3.65$-3.37
High Forecast$-3.29$-3.12
Low Forecast$-3.87$-3.70
Surprise %-89.59%-15.13%

Revenue Forecast

Dec 24 Dec 25
Dec 24Dec 25
Reported--
Avg Forecast--
High Forecast--
Low Forecast--
Surprise %--

Net Income Forecast

$-650M $-530M $-410M $-290M $-170M $-50M Dec 24 Dec 25
Dec 24Dec 25
Reported$-78.31M$-111.48M
Avg Forecast$-599.89M$-553.87M
High Forecast$-540.72M$-512.78M
Low Forecast$-636.05M$-608.11M
Surprise %-86.95%-79.87%

RAPP Forecast FAQ

Is Rapport Therapeutics stock a buy?

Rapport Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rapport Therapeutics is a favorable investment for most analysts.

What is Rapport Therapeutics's price target?

Rapport Therapeutics's price target, set by 5 Wall Street analysts, averages $43.5 over the next 12 months. The price target range spans from $40 at the low end to $47 at the high end, suggesting a potential 51.73% change from the previous closing price of $28.67.

How does Rapport Therapeutics stock forecast compare to its benchmarks?

Rapport Therapeutics's stock forecast shows a 51.73% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rapport Therapeutics over the past three months?

  • March 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.